市場調查報告書
商品編碼
1394581
全球癌症診斷市場評估:按產品類型、技術、癌症類型、最終用戶、地區、機會、預測(2016-2030)Cancer Diagnostics Market Assessment, By Product, By Technology, By Cancer Type, By End-user, By Region, Opportunities and Forecast, 2016-2030F |
全球癌症診斷市場規模預計將從 2022 年的 1,475 億美元增至 2030 年的 2,386.6 億美元,2023-2030 年預測期間複合年增長率為 6.2%。Masu。 由於全球癌症患者數量不斷增加,預計該市場將大幅成長。 癌症發生率的快速增加可歸因於遺傳變異、飲酒和吸煙、荷爾蒙和生活方式的改變、致癌微生物感染以及污染增加,這些因素在推動癌症診斷市場的重要因素中發揮作用。 診斷中心數量的增加也是全球癌症診斷市場的驅動因素。 這將有助於增加癌症篩檢,從而帶來更好的結果。 人工智慧和機器學習等技術在癌症診斷和預測中的結合正在推動癌症診斷市場的成長。 此外,擴大產業聯盟、創新和先進產品的推出以及政府促進癌症篩檢的措施預計將在預測期內推動市場成長。 然而,與癌症診斷程序相關的高成本以及缺乏熟練的專業人員進行癌症篩檢可能會阻礙市場成長。
2023 年 7 月,診斷資訊服務先驅 Quest Diagnostics 宣布透過其專業病理學公司 AmeriPath 與 Envision Sciences 合作推出新的前列腺癌生物標記測試。 這項新的基於組織的檢測服務旨在幫助滿足臨床對診斷的迫切需求,該診斷可以區分男性前列腺癌的侵襲性和非侵襲性病例。 生物標記測試的前沿發展預計將在推動癌症診斷市場方面發揮關鍵作用。
無論是在已開發國家或發展中國家,癌症都是全球主要死亡原因之一。 近年來,生活習慣、菸酒攝取、輻射暴露等發生了顯著變化,這些都是癌症的主要原因。 由於這些因素,癌症患者的數量正在迅速增加。 早期檢測癌症以進行有效治療的診斷技術的進步正在推動癌症診斷市場的需求。 在這種情況下,癌症篩檢對於降低相關死亡率非常重要,從而進一步促進全球癌症診斷市場的成長。
根據世界衛生組織(WHO)的數據,2020年新診斷癌症患者人數為19,292,789人,預計到2025年將增至21,618,445人,增長率為12.1%。 截至2020年底,過去五年已有780萬名女性被診斷出罹患乳癌,使其成為世界上最常見的癌症。
隨著癌症患者數量的日益增加,對癌症篩檢的需求也在不斷增加,並且由於發展中國家公共醫療設施中可用的診斷成像技術有限,許多私人診斷中心正在擴大我們的分支機構。 除了私人診斷設施外,還建立了政府資助的診斷實驗室以促進癌症篩檢。 市場進入者正在與現有組織合作建立或翻新癌症診斷設施。 此外,各種診斷公司正在不同地區擴大業務。 因此,診斷中心的增加預計將推動市場成長。
例如,2023 年 3 月,克利夫蘭診所最先進的癌症設施法蒂瑪·賓特·穆巴拉克中心在阿布扎比克利夫蘭診所開業。 新的癌症醫院將為阿聯酋和中東地區的癌症診斷和治療提供全面和創新的方法。 由於新診所,患者將不再需要飛往海外才能接受基本護理和治療。 Fatima bint Mubarak 中心擁有診斷設施、24 個用於靜脈注射藥物的私人房間以及 32 個用於多學科癌症檢查的檢查室。
本報告研究和分析了全球癌症診斷市場,提供市場規模和預測、市場動態以及主要參與者的現狀和前景。
The Global cancer diagnostics market size was valued at USD 147.5 billion in 2022 and is expected to reach USD 238.66 billion in 2030 with a CAGR of 6.2% for the forecast period between 2023 and 2030F. As per WHO, cancer is the second leading cause of death around the world. Healthcare professionals and market players are focused on developing more advanced solutions for early cancer diagnosis to reduce the cancer burden. Cancer screening is performed through several techniques depending on the site and type of cancer. The global cancer diagnostics market is expected to grow exponentially due to the increasing number of cancer cases around the world. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, carcinogenic microbial infections, and increasing pollution, which play an important role in driving the cancer diagnostics market. Growth in the number of diagnostic centers is also a driving force for the global cancer diagnostics market. It promotes a high number of cancer screenings leading to better outcomes. The inclusion of technologies like artificial intelligence, and machine learning, for the diagnosis and prediction of cancer is driving the growth in the cancer diagnostics market. Additionally, growing industry collaborations, innovative and advanced product launches, and government initiatives to boost cancer screening are anticipated to drive market growth during the forecast period. However, the high costs associated with cancer diagnostic procedures and lack of skilled professionals to perform cancer screenings may hinder market growth.
In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men. Cutting-edge developments in biomarker tests are expected to play a significant role in driving the cancer diagnostics market.
Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. In recent years, a notable change in lifestyle, tobacco and alcohol consumption, and radiation exposure, has been observed which are the leading causes of cancer. Due to these factors, the number of cancer cases has increased drastically. Diagnostic advancement for early detection when cancer can be effectively treated increases the demand in the cancer diagnostics market. Cancer screening becomes crucial in this scenario to reduce associated mortality, further boosting the growth of the global cancer diagnostics market.
As per the World Health Organization, there were 19,292,789 newly diagnosed cancer cases in 2020 which is expected to increase to 21,618,445 with a growth rate of 12.1% by 2025. By 2020-year end, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world's most prevalent cancer.
As the number of cancer cases is increasing day by day, the demand for cancer screening is also increasing, and due to limited imaging techniques available at public healthcare facilities in developing countries, numerous private diagnostic centers are expanding their branches. Besides private diagnostic establishments, government-funded diagnostic laboratories are also being established to facilitate cancer screening. The market players collaborate with existing organizations to establish or revamp cancer diagnostic facilities. Various diagnostic companies are also expanding their businesses across different geographies. Thus, growth in the number of diagnostic centers is expected to drive growth in the market.
For instance, in March 2023, The Fatima bint Mubarak Center, a brand-new, cutting-edge cancer facility from Cleveland Clinic, opened at Cleveland Clinic Abu Dhabi. In the United Arab Emirates and the Middle East, the new cancer hospital offers a comprehensive and revolutionary approach to cancer diagnosis and treatment. Patients won't have to fly overseas to receive the essential care and treatment, thanks to the new clinic. The Fatima bint Mubarak Center features diagnostic facilities, 24 private infusion rooms for intravenous medicine administration, and 32 exam rooms for multidisciplinary cancer consultations.
Cancer diagnostics research and development of screening tests and products is quite an extensive process that requires a lot of funding. The funding for cancer screening research mainly comes from market players as well as government authorities. In the global cancer diagnostics market, government organizations, associations, and agencies actively promote cancer screening and treatments by providing research funds and driving awareness initiatives, thereby fostering market growth. Additionally, government policies supporting the manufacturing and distribution of cancer diagnostic products are also driving growth in the global cancer diagnostics market.
For instance, according to a press release from The White House, in March 2023, the United States government invested 394.5 million USD in National Comprehensive Cancer Control Program, which includes the Cancer Genomics Program, the National Breast and Cervical Cancer Early Detection Programs to improve various cancer screening and diagnostic services for uninsured and underinsured American women, and the Colorectal Cancer Control Program to increase colorectal cancer screening rates among people age 45 to 75.
In January 2023, the United Kingdom government announced a 10-million-euro investment to develop 29 new breast cancer screening units, these units will be dedicated to reducing the breast cancer burden of the UK. Such government support initiatives and funding for breast cancer research, diagnosis, and treatment are anticipated to drive market growth for the global cancer diagnostics market.
The rapid growth of this sector can be attributed to the strong inclination of physicians towards in-vitro diagnostics products for cancer diagnosis. Significant progress has been made in the global market for cancer diagnostics, revolutionizing the detection and treatment of cancer. Advancements in liquid biopsies, next-generation sequencing technology, and molecular diagnostics have enhanced individualized therapy methods and early detection. Targeted medicines, improved patient outcomes, and fewer side effects have been made possible by biomarker identification and accompanied diagnostic testing. Furthermore, the utilization of artificial intelligence and machine learning algorithms has proven to be crucial in analyzing intricate data, enabling more precise diagnosis, and forecasting of treatment outcomes. Ongoing developments in oncology within the field of in vitro diagnostics are revolutionizing cancer care and providing fresh hope in the fight against cancer. Additionally, the segment's expansion is projected to gain momentum due to the growing number of breast cancer patients worldwide.
For instance, in November 2022, Google Health announced a financial agreement with iCAD (a leading market player focused on cancer detection and medical technology development). Through this partnership, iCAD can incorporate Google Health's mammography AI research model in its products for clinical usage. This advancement will help in better and more precise diagnosis of breast cancers.
Different aspects of healthcare were affected by COVID-19. The global market for cancer diagnostics experienced a notable decline as a result of government-imposed lockdowns and preventive measures across the globe. The market witnessed a reduction in cancer screening.
In addition, several elective examinations, operations, and treatments were canceled or postponed because of preventive restrictions for COVID-19. A report that was published in SAGE in June 2022 states that there was a 44% drop in screening mammography for breast cancer between 2019 and 2020. Despite the COVID-19 pandemic's effects, telehealth initiatives and the application of AI and machine learning gave rise to opportunities for several digital businesses to produce cutting-edge solutions for early cancer detection and prediction. Thus, the overall COVID-19 pandemic negatively affected the screening and treatment rate of cancer but also contributed to technological advancements.
Market players have employed a range of strategies to increase the range of solutions they offer and give the customers access to a wide range of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic services they offer to capture a bigger portion of the market. Many major industry players are using both different growth techniques, like partnerships, mergers and acquisitions; and the development and launch of new products, to strengthen their position in the global market.
In June 2022, Roche announced the release of its newest cutting-edge tissue staining platform, the BenchMark ULTRA PLUS system, for doctors to decide on a patient's course of therapy in a timely manner, the system provides rapid and accurate test results. Several innovations are included in the new system, including an integrated touchscreen for an enhanced user experience, new intuitive software, remote monitoring capabilities, and more environmentally friendly product packaging and waste management.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.